Based on its exclusive nitroalkane chemistry, ANGUS Chemical Company supplies globally registered buffers and biochemicals to the life science industry, including TRIS AMINO®products for buffering, neutralizing, solubilizing and stabilizing.
From pilot to commercial-scale production, ANGUS Chemical Company supplies globally registered buffers and biochemicals to the life science industry. Based on ANGUS’s exclusive nitroalkane chemistry and its derivatives, TRIS AMINO® products have become a standard resource material and are excellent buffers, neutralizers, solubilizers and stabilizers for pharmaceutical, ophthalmic and other life science formulations and processes. All TRIS AMINO products are water, alcohol and glycol soluble and can be used to buffer anywhere within the pH range of 7 to 9. ANGUS is the only back integrated manufacturer of cGMP certified TRIS AMINO, and our commitment to best-in-class operating performance ensures a consistent supply of high-quality product that meets the most stringent specifications. Like all of our specialty additives, our TRIS AMINO products are fully supported with localized technical expertise, regulatory assistance and formulation guidance from our global network of Customer Application Centers. We can also offer customized testing, certifications, as well as custom blending and specialized packaging. Plus, our chemistry can be customized to meet a wide variety of needs.
Contact details:
Email: info@angus.com Web Address: www.angus.com
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.